Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syndax PharmaceuticalsFRA:1T3 -4.37%20 Net Current Asset Value is €0.39 as of Mar. 2026, which is 100% below its 10-year median of 3.90. GuruFocus rates FRA:1T3 with a GF Score™ of 20/100. The stock has 9 warning signs investors should review. Among 941 Biotechnology companies, Syndax Pharmaceuticals ranks worse than 94.79% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Syndax Pharmaceuticals's net current asset value per share for the quarter that ended in Mar. 2026 was €0.39.
The historical rank and industry rank for Syndax Pharmaceuticals's Net Current Asset Value or its related term are showing as below:
FRA:1T3'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.56 Med: 3.9 Max: 51.91
Current: 51.26
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Syndax Pharmaceuticals was 51.91. The lowest was 1.56. And the median was 3.90.
FRA:1T3's Price-to-Net-Current-Asset-Value is ranked worse than 94.79% of 941
companies
in the Biotechnology industry
Industry Median: 4.81
vs FRA:1T3: 51.26
Syndax Pharmaceuticals (FRA:1T3) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Syndax Pharmaceuticals Net Current Asset Value Related Terms
Syndax Pharmaceuticals Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Syndax Pharmaceuticals's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syndax Pharmaceuticals Net Current Asset Value Chart
FRA:1T3 vs IOVA, GLUE, TYRA: Net Current Asset Value Comparison
For the Biotechnology subindustry, Syndax Pharmaceuticals's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syndax Pharmaceuticals Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Syndax Pharmaceuticals's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of €0.39 mean?
Syndax Pharmaceuticals (FRA:1T3) has a Net Current Asset Value of €0.39 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Syndax Pharmaceuticals and its competitors. This is 90% below median its historical median of 3.90. Over the past decade, Syndax Pharmaceuticals' Net Current Asset Value has ranged from 1.56 to 51.91. According to the industry distribution chart, Syndax Pharmaceuticals ranks #892 out of 941 companies in the Biotechnology industry, placing it in the top 94.8%.
Is Syndax Pharmaceuticals' Net Current Asset Value too high?
Syndax Pharmaceuticals' current Net Current Asset Value of €0.39 is 90% below median its 10-year median of 3.90. Over the past 10 years, this metric has ranged from a low of 1.56 to a high of 51.91. Based on the distribution chart, Syndax Pharmaceuticals ranks #892 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Syndax Pharmaceuticals has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Syndax Pharmaceuticals' Net Current Asset Value compare to IOVA and GLUE?
According to the Biotechnology industry distribution chart, Syndax Pharmaceuticals ranks #892 out of 941 companies for Net Current Asset Value. This places Syndax Pharmaceuticals in the lower half of its industry. The industry median Net Current Asset Value is 4.81. Historically, Syndax Pharmaceuticals' own Net Current Asset Value has ranged from 1.56 to 51.91 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.81, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Syndax Pharmaceuticals and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syndax Pharmaceuticals's current Net Current Asset Value is €0.39, which is 90% below median its own 10-year median of 3.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syndax Pharmaceuticals stock overvalued right now?
Syndax Pharmaceuticals (FRA:1T3) has a current Net Current Asset Value of €0.39. The current Net Current Asset Value is €0.39, which is 90% below median its 10-year median of 3.90. Syndax Pharmaceuticals' overall GF Score™ is 20/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Syndax Pharmaceuticals (FRA:1T3), the current Net Current Asset Value is €0.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
20GF Score
Get the complete analysis for FRA:1T3
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1T3 has been successfully added to your 
